{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meneveau MO"],"funding":["NCI","NHLBI NIH HHS","Melanoma Research Alliance","NCI NIH HHS","Cancer Research Institute"],"pagination":["e003533"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8919469"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(3)"],"pubmed_abstract":["<h4>Background</h4>A goal of cancer vaccines is to induce strong T cell responses to tumor antigens, but the delivery method, schedule, and formulation of cancer vaccines have not yet been optimized. Adjuvants serve to increase the immune response against vaccine antigens. However, little is known about the impact of adjuvants plus antigen and their delivery schedule on the immunologic milieu in the vaccine-site microenvironment (VSME). We hypothesized that antigen processing and presentation may occur directly in the VSME, that adding the toll-like receptor 3 (TLR3) agonist polyICLC (pICLC) would enhance markers of immune activation, and that the immune signatures would be enhanced further by repeated vaccination in the same skin site rather than after multiple vaccines in different skin "],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling."],"pmcid":["PMC8919469"],"funding_grant_id":["T32 HL007849","T32HL007849","R01 CA178846","CLIP award","R01 CA057653","RO1 CA178846","210369","T32 CA163177","P30 CA044579"],"pubmed_authors":["Lynch KT","Meneveau MO","Kumar P","Patel SP","Slingluff CL"],"additional_accession":[]},"is_claimable":false,"name":"The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling.","description":"<h4>Background</h4>A goal of cancer vaccines is to induce strong T cell responses to tumor antigens, but the delivery method, schedule, and formulation of cancer vaccines have not yet been optimized. Adjuvants serve to increase the immune response against vaccine antigens. However, little is known about the impact of adjuvants plus antigen and their delivery schedule on the immunologic milieu in the vaccine-site microenvironment (VSME). We hypothesized that antigen processing and presentation may occur directly in the VSME, that adding the toll-like receptor 3 (TLR3) agonist polyICLC (pICLC) would enhance markers of immune activation, and that the immune signatures would be enhanced further by repeated vaccination in the same skin site rather than after multiple vaccines in different skin ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-06-15T06:06:52.402Z","creation":"2025-04-04T08:01:19.683Z"},"accession":"S-EPMC8919469","cross_references":{"pubmed":["35277457"],"doi":["10.1136/jitc-2021-003533"]}}